Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program [Original Articles]

Conclusions— In this national cohort, 18% of patients undergoing PCI had contraindications to common antiplatelet medications. Approximately 6% of those patients received a contraindicated medication with attendant bleeding risk, although this did not translate into significantly higher risk of 30-day mortality. Continued efforts to reduce contraindicated medication use may help avoid periprocedural complications.
Source: Circulation: Cardiovascular Quality and Outcomes - Category: Cardiology Authors: Tags: Platelets, Anticoagulants, Percutaneous Coronary Intervention, Stent, Quality and Outcomes Original Articles Source Type: research